Results 241 to 250 of about 5,096,258 (344)

Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney [PDF]

Jean‐Michel Halimi, Pantelis Sarafidis, Michel Azizi, Grzegorz Bilo, Thilo Burkard, Michael Bursztyn, Miguel Camafort, Neil Chapman, Santina Cottone, Tine De Backer, Jaap Deinum, P. Delmotte, Maria Dorobanţu, Michael Doumas, Rainer Düsing, Béatrice Bouhanick, Jean‐Pierre Fauvel, Pierre Fesler, Zbigniew Gaciong, Εugenia Gkaliagkousi, Daniel Gordin, Guıdo Grassı, Charalampos Grassos, Dominique Guerrot, Justine Huart, Raffaele Izzo, Fernando Jaén Águila, Zoltán Járai, Thomas Kahan, Ilkka Kantola, Eva Kociánová, FlorianP. Limbourg, Marilucy Lopez‐Sublet, Francesca Mallamaci, Athanasios Manolis, Maria Marketou, Gert Mayer, Alberto Mazza, IainM. MacIntyre, Jean‐Jacques Mourad, María Lorenza Muiesan, Edgar Nasr, Peter M. Nilsson, Anna Oliveras, Olivier Ormezzano, Vítor Paixão Dias, John A. Papadakis, Dimitris Papadopoulos, Sabine Perl, Jorge Polónia, Roberto Pontremoli, Giacomo Pucci, Nicolás Roberto Robles, Sébastien Rubin, Luís M. Ruilope, Lars Christian Rump, Sahrai Saeed, Elias Sanidas, Riccardo Sarzani, Roland E. Schmieder, François Silhol, Dragan Lović, Marit D. Solbu, Miroslav Souček, George S. Stergiou, Isabella Sudano, Ramzi Tabbalat, İstemihan Tengiz, Helen Triantafyllidi, K. Tsioufis, J. Václavík, Markus van der Giet, Patricia Van der Niepen, Franco Veglio, R.M. Venzin, Margus Viigimaa, Thomas Weber, J Widimský, Grégoire Wuerzner, Parounak Zelveian, Pantelis Zebekakis, Stephan Lueders, Alexandre Persu, Reinhold Kreutz, Liffert Vogt   +84 more
openalex   +1 more source

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini, Emanuela Martinuzzi, Sandra Dhifallah, Abderhmane Slioui, Angela Puma, Luisa Villa, Michele Cavalli, Andra Ezaru, Jérémy Garcia, Manuela Gambella, Federico Torre, Luca Jacopo Pavan, Nicolas Glaichenhaus, Sabrina Sacconi   +13 more
wiley   +1 more source

Relapsing–Remitting Multiple Sclerosis Is Associated With a Dysbiotic Oral Microbiome

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation, demyelination, and neurological impairment. While the gut microbiota's role in MS is extensively studied, the association between the oral microbiota and MS remains underexplored, particularly in North American cohorts.
Sukirth M. Ganesan, Meeta Yadav, Sudeep Ghimire, Peter C. Lehman, Apurva J. Patel, Sydney Woods, Heena Olalde, Jemmie Hoang, Mishelle Paullus, Catherine Cherwin, Christine Gill, Tracey Cho, Ashutosh K. Mangalam   +12 more
wiley   +1 more source

Barriers to Chronic Disease Healthcare Access in Rural Eastern Cape Province, South Africa. [PDF]

Int J Environ Res Public Health
Mntungwana S, Khosa NV, Buso AE, Sithole N.   +3 more
europepmc   +1 more source

Scanning the chronic disease terrain: prospects and opportunities.

, 2014
Jeremiah A. Barondess
openalex   +1 more source

Accelerated Progression of Gait Impairment in Parkinson's Disease and REM Sleep Without Atonia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective People with Parkinson's disease (PD) and rapid eye movement (REM) sleep without atonia (RSWA) often have more severe gait disturbances compared to PD without RSWA. The association between the presence and expression of RSWA and the rate of progression of gait impairment in PD is unknown.
Sommer L. Amundsen‐Huffmaster, Jae Woo Chung, Maria E. Linn‐Evans, Matthew N. Petrucci, Chiahao Lu, Destiny J. Weaver, Joshua De Kam, Scott E. Cooper, Paul J. Tuite, Aleksandar Videnovic, Michael J. Howell, Colum D. MacKinnon   +11 more
wiley   +1 more source

Digital Health Interventions to Support Chronic Disease Management: Systematic Scoping Review.

JMIR Mhealth Uhealth
Al Mahmud A, Joachim S, Jayaraman PP, Learmonth C, Tyagi S, Forkan ARM, Shuakat M, Wickramasinghe N, Wheeler J, Best S, Trainer A.   +10 more
europepmc   +1 more source

Gamification-Based Interventions in Chronic Disease Care: A Systematic Review of Randomised Controlled Trials. [PDF]

Risk Manag Healthc Policy
Emaliyawati E, Ibrahim K, Kurniawan T, Fitria N, Songwathana P.   +4 more
europepmc   +1 more source

A biological perspective for the management of chronic obstructive pulmonary disease by testosterone

, 2014
Cristian Cojocaru, Adina Turcanu, T Mihăescu, Alin Ciobîcă, Daniel Timofte, Ovidiu Alexinschi, Emil Anton, Elena Cojocaru   +7 more
openalex   +2 more sources

CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Neuronal pentraxin 2 (NPTX2) is a synaptic protein involved in synaptic plasticity and regulation of neuronal excitability. Lower baseline cerebrospinal fluid (CSF) NPTX2 levels have been shown to be associated with an earlier onset of mild cognitive impairment (MCI), a pre‐dementia syndrome, even after CSF Alzheimer's Disease (AD)
Juan P. Vazquez, Corinne Pettigrew, Yuxin Zhu, Claire Anderson, Guray Erus, Christos Davatzikos, Michael Miller, Abhay Moghekar, Sungtaek Oh, Chan‐Hyun Na, Marilyn Albert, Paul Worley, Anja Soldan   +12 more
wiley   +1 more source